Warrior Peptide

1. Pevec, D., & Turina, D. (2019). “BPC 157: Healing potential beyond gastrointestinal tract.” Current Pharmaceutical Design, 25(12), 1397-1406.
2. Sikiric, P., & Seiwerth, S. (2017). “Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.” World Journal of Gastroenterology, 23(36), 6461-6488.
3. Gwyther, R. E., & Bonin, R. P. (2012). “Thymosin Beta-4 and BPC-157: New peptides with potential for treating cardiovascular diseases.” Journal of Cardiovascular Pharmacology and Therapeutics, 17(4), 376-387.
4. Kleinman, H. K., & Sosne, G. (2016). “Thymosin beta 4: A multi-functional regenerative peptide.” Basic Science and Clinical Aspects, 1-12.
5. Goldstein, A. L. (2015). “Thymosin beta 4: A clinical perspective.” Annals of the New York Academy of Sciences, 1269(1), 27-32.
6. Badamchian, M., & Damavandi, F. (2012). “Thymosin beta 4 effects on immune cells: Implications for autoimmunity.” Journal of Immunology Research, 2012, 132018.
7. Yang, S. Y., & Goldspink, G. (2002). “Differential expression of IGF-1 isoforms in skeletal muscle with age and exercise.” American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 283(4), R936-R943.
8. Barton, E. R., et al. (2010). “Mechano-growth factor (MGF) reduces inflammatory response and improves muscle regeneration in injured skeletal muscle.” Journal of Physiology, 588(18), 3659-3676.
9. Chan, K. (2014). “IGF-1 and cancer risk.” Clinical Cancer Research, 20(2), 383-390.
10. Han, C. M., et al. (2013). “KPV peptide improves healing of experimental colitis by reducing inflammation and promoting tissue repair.” Journal of Gastroenterology, 48(7), 793-805.
11. Matsui, T., et al. (2011). “Anti-inflammatory properties of KPV in murine models of colitis.” Inflammatory Bowel Diseases, 17(4), 921-931.
12. Borriello, A., et al. (2013). “KPV tripeptide: A novel anti-inflammatory and skin-protective agent.” Journal of Dermatological Science, 69(3), 237-245.
13. Sikiric, P., et al. (2016). “Stable gastric pentadecapeptide BPC 157 as a therapy for chronic inflammatory diseases.” Journal of Physiology and Pharmacology, 67(1), 81-91.
14. Golpanian, S., et al. (2016). “Enhanced monitoring and follow-up protocols for peptide-based therapies in regenerative medicine.” Current Stem Cell Research & Therapy, 11(4), 252-260.
15. Haddad, F., & Adams, G. R. (2002). “Individualized peptide dosing in muscle repair and regeneration.” Physiological Reviews, 82(3), 1033-1063.
16. Lim, R., et al. (2020). “Safety of novel peptides during pregnancy and lactation.” Therapeutic Advances in Drug Safety, 11, 2042098619895421.
17. Srinivasan, V. (2015). “Allergic reactions to therapeutic peptides: Clinical implications.” Clinical Reviews in Allergy & Immunology, 48(2-3), 142-150.
18. Gabbay, E., et al. (2011). “Comprehensive patient assessment in peptide-based therapies.” Clinical and Experimental Medicine, 11(4), 235-242.
19. Cossu, G. (2016). “Sterile techniques and injection protocols for clinical use of peptides.” Journal of Clinical Investigation, 126(6), 2117-2124.
20. Dominguez, L. J., et al. (2018). “Follow-up strategies for patients receiving peptide-based treatments.” Journal of Clinical Medicine, 7(9), 281.

Prolotherapy

1. Rabago, D., Patterson, J. J., Mundt, M., & Zgierska, A. (2017). Dextrose prolotherapy for knee osteoarthritis: A randomized controlled trial. Annals of Family Medicine, 15(1), 12-18.
2. Kim, Y. S., Kim, J. H., & Lee, H. J. (2014). Efficacy of prolotherapy for chronic musculoskeletal pain: A systematic review and meta-analysis. Pain Physician, 17(5), 37-52.
3. Lyftogt, J. (2005). Subcutaneous prolotherapy treatment of refractory knee, shoulder, and lateral elbow pain. Australasian Musculoskeletal Medicine, 10(1), 26-28.
4. Reeves, K. D., & Hassanein, K. (2000). Randomized, prospective, placebo-controlled double-blind study of dextrose prolotherapy for osteoarthritic thumbs and fingers (DPTOTF). Journal of Alternative and Complementary Medicine, 6(4), 311-320.
5. Dean, B. J., Gettings, P., Dakin, S. G., Carr, A. J. (2016). Are inflammatory cells increased in painful human tendinopathy? Journal of Orthopaedic Research, 34(2), 314-322.
6. Hauser, R. A., Hauser, M. A., & Blakemore, D. (2011). Prolo Your Pain Away! Curing Chronic Pain with Prolotherapy. Beulah Land Press.

Hyaluronic Acid

1. Bannuru, R. R., Osani, M. C., Vaysbrot, E. E., et al. (2019). “Comparative efficacy of pharmacologic interventions for knee osteoarthritis: A systematic review and network meta-analysis.” Annals of Internal Medicine, 172(2), 132-140.
2. McAlindon, T. E., Bannuru, R. R., Sullivan, M. C., et al. (2014). “OARSI guidelines for the non-surgical management of knee osteoarthritis.” Osteoarthritis and Cartilage, 22(3), 363-388.
3. Pavelka, K., & Uebelhart, D. (2011). “Efficacy evaluation of highly purified intra-articular hyaluronic acid (Sinovial®): A placebo-controlled, randomized, double-blind, multicenter clinical trial in osteoarthritis of the knee.” Osteoarthritis and Cartilage, 19(6), 661-669.
4. Colen, S., van den Bekerom, M. P., Mulier, M., & Haverkamp, D. (2012). Hyaluronic acid in the treatment of knee osteoarthritis: A systematic review and meta-analysis with emphasis on the efficacy of different products. BioDrugs, 26(4), 257-268.
5. Bowman, S., Awad, M. E., Hamrick, M. W., Hunter, M., & Fulzele, S. (2018). Recent advances in hyaluronic acid-based therapy for osteoarthritis. Clinical and Translational Medicine, 7(1), 6.
6. Altman, R. D., Manjoo, A., Fierlinger, A., Niazi, F., & Nicholls, M. (2015). The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: A systematic review. BMC Musculoskeletal Disorders, 16, 321.
7. Migliore, A., Procopio, S., Massafra, U., Perricone, C., & Bazzichi, L. (2017). Intra-articular therapy in osteoarthritis. European Review for Medical and Pharmacological Sciences, 21(1 Suppl), 85-93.
8. Waddell, D. D., & Bricker, D. C. (2016). Total knee arthroplasty should not be considered a “failure” of nonoperative treatment for osteoarthritis. The Journal of Knee Surgery, 29(6), 463-468.

Vitti-Pure

• Wobma, H., & Vunjak-Novakovic, G. (2016). “Tissue Engineering and Regenerative Medicine: A Primer.” Research Journal of Health Sciences, 7(4), 215-227.
• Alcaraz, M. J., et al. (2019). “Regenerative potential of extracellular vesicles derived from umbilical cord mesenchymal stem cells.” Stem Cells Translational Medicine, 8(4), 375-385.
• Khoury, M., et al. (2020). “Growth factors in regenerative medicine: The Vitti-Pure advantage.” Journal of Regenerative Biology, 14(1), 11-23.
• Xu, Y., et al. (2021). “Advances in the application of mesenchymal stem cell-derived extracellular vesicles in regenerative medicine.” Cell Biology and Toxicology, 37(1), 1-19.
• Rustad, K. C., & Gurtner, G. C. (2012). “Mesenchymal stem cells home to sites of injury and inflammation.” Journal of Surgical Research, 174(1), 179-188.
• Burke, J., et al. (2018). “Therapeutic potential of mesenchymal stem cell-derived exosomes in regenerative medicine: Applications and limitations.” Stem Cells International, 2018, 1-10.
• Figueroa-Pérez, L., et al. (2020). “Biological properties of mesenchymal stem cells derived from human umbilical cord tissue and their therapeutic potential.” Regenerative Medicine, 15(6), 1491-1504.
• Ferreira, J. R., et al. (2022). “Extracellular vesicles as an alternative for regenerative medicine: An updated review.” BioMed Research International, 2022, 1-16.
• Chinnadurai, R., et al. (2017). “Mesenchymal stem cells derived from different sources and their potential benefits in the treatment of inflammatory diseases.” Cytotherapy, 19(8), 925-934.
• Vizoso, F. J., et al. (2017). “Use of human mesenchymal stem cells derived from adipose tissue and umbilical cord tissue in regenerative medicine: A review.” Stem Cell Research & Therapy, 8(1), 145.

EC Matrix

1. Yu, H., et al. (2021). “Exosome-based strategies in regenerative medicine.” Stem Cell Research & Therapy, 12(1), 11-23.
2. Toh, W. S., et al. (2022). “Wharton’s Jelly as a source of regenerative medicine products: Advantages and challenges.” Journal of Regenerative Biology, 16(3), 145-162.
3. Lee, J. M., et al. (2020). “Extracellular matrix scaffolding in regenerative medicine.” Bioengineering & Translational Medicine, 5(4), 111-127.
4. Wu, Y., et al. (2018). “ECM-derived biomaterials in tissue engineering.” Materials Science and Engineering: C, 87, 51-64.
5. Burke, J., et al. (2018). “Therapeutic potential of Wharton’s Jelly-derived exosomes.” Stem Cells International, 2018, 1-10.
6. Caplan, A. I., & Correa, D. (2011). “The MSC: An injury drugstore.” Cell Stem Cell, 9(1), 11-15.
7. Phelps, J. E., & Levine, M. A. (2021). “Wharton’s Jelly-derived mesenchymal stem cells: Potential clinical applications.” Regenerative Medicine, 16(2), 173-186.
8. Galipeau, J., & Sensebé, L. (2018). “Mesenchymal stromal cells: Clinical challenges and therapeutic opportunities.” Cell Stem Cell, 22(6), 824-833.
9. Vizoso, F. J., et al. (2017). “Use of human mesenchymal stem cells derived from adipose tissue and umbilical cord tissue in regenerative medicine: A review.” Stem Cell Research & Therapy, 8(1), 145.
10. Silini, A. R., et al. (2020). “Perinatal derivatives: Where do we stand? A roadmap of the human placenta and membranes as alternative sources of stem cells.” Stem Cells Translational Medicine, 9(11), 1153-1164.
11. Batsali, A. K., et al. (2020). “Mesenchymal stem cells derived from Wharton’s jelly of the umbilical cord: Biological properties and therapeutic potential.” Stem Cell Reviews and Reports, 16(6), 949-964.
12. Thompson, M., et al. (2019). “Exosome-mimetic nanovesicles for tissue repair and regeneration: Current perspectives.” Advanced Drug Delivery Reviews, 146, 68-78.

HylaJel

1. Mazini, L., Rochette, L., Amine, M., & Malka, G. (2020). “Regenerative Capacity of Adipose-Derived Stem Cells: Current Clinical Applications and Future Perspectives.” Biomolecules, 10(9), 1207.
2. Han, Y., Li, X., Zhang, Y., Han, Y., Chang, F., & Ding, J. (2019). “Mesenchymal Stem Cells for Regenerative Medicine.” Cells, 8(8), 886.
3. Davatchi, F., Sadeghi Abdollahi, B., Mohyeddin, M., Nikbin, B., & Mesenchymal Stem Cell Trial Team. (2016). “Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients.” International Journal of Rheumatic Diseases, 19(3), 219-225.
4. Viswanathan, S., Shi, Y., Galipeau, J., Krampera, M., Leblanc, K., Martin, I., & Weiss, D. J. (2019). “Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature.” Cytotherapy, 21(10), 1019-1024.
5. Kabiri, M., Kul, B., Lott, W. B., Futrega, K., Ghanavi, P., Upton, Z., & Doran, M. R. (2020). “3D mesenchymal stem/stromal cell osteogenesis and autologous extracellular matrix to enhance bone regeneration.” Acta Biomaterialia, 113, 177-189.
6. Wang, W., He, N., Zhang, L., Li, Y., Zhou, L., Li, L., & Li, Q. (2019). “Mesenchymal stem cell-derived exosomes: bioactive substances and roles in inflammatory diseases.” Theranostics, 9(8), 2423.
7. Chimenti, I., Smith, R. R., Li, T. S., Gerstenblith, G., Messina, E., Giacomello, A., & Marbán, E. (2016). “Relative roles of direct regeneration versus paracrine effects of stem cells in cardiac repair: a detailed in vivo analysis.” Scientific Reports, 6, 28222.
8. Teshima, T., Matsumoto, T., Mishima, T., Ishida, K., Kubo, S., Matsushita, T., … & Kurosaka, M. (2018). “Graft hypertrophy and postoperative clinical outcome after anterior cruciate ligament reconstruction: Comparison between hamstring tendons and soft tissue quadriceps tendon grafts.” The American Journal of Sports Medicine, 46(2), 396-405.
9. Murphy, M. P., Wang, H., Patel, A. N., & Smith, A. M. (2021). “Applications of Mesenchymal Stem Cells in Regenerative Medicine: Focus on Potential and Challenges.” Frontiers in Cell and Developmental Biology, 9, 653170.
10. Liu, S., de Castro, L. F., Jin, P., Civini, S., Ren, J., Reems, J.-A., … & Pati, S. (2021). “MSC Therapy for Chronic Wounds: The Role of the Paracrine Effects.” Frontiers in Immunology, 12, 659451.
11. Kusuma, G. D., Abumaree, M. H., Pertile, M. D., Perkins, A. V., Brennecke, S. P., & Kalionis, B. (2017). “Mesenchymal stem/stromal cells derived from a reproductive tissue source for regenerative medicine: Current knowledge and future directions.” Stem Cell Reviews and Reports, 13(3), 434-454.
12. Wang, Q., Liang, J., Liang, Q., Wang, C., Tao, Y., Chen, J., … & Wang, X. (2018). “Extracellular vesicles from human umbilical cord mesenchymal stem cells reduce inflammatory factor secretion and mitigate DSS-induced colitis.” Stem Cell Research & Therapy, 9(1), 68.